# A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC

> **NCT00743938** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 141 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** BMS-690514
- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT00743938
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2010-08
- **Final completion:** 2012-06
- **Target enrollment:** 141 (ACTUAL)
- **Last updated:** 2015-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00743938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00743938, "A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT00743938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*